Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
Harrison, Stephen A., Bashir, Mustafa, Moussa, Sam E., McCarty, Kevin, Pablo Frias, Juan, Taub, Rebecca, Alkhouri, Naim
Published in Hepatology communications (01.04.2021)
Published in Hepatology communications (01.04.2021)
Get full text
Journal Article
Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose
Published in Obesity (Silver Spring, Md.) (01.01.2019)
Published in Obesity (Silver Spring, Md.) (01.01.2019)
Get full text
Journal Article
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Frias, Juan Pablo, Nauck, Michael A, Van, Joanna, Kutner, Mark E, Cui, Xuewei, Benson, Charles, Urva, Shweta, Gimeno, Ruth E, Milicevic, Zvonko, Robins, Deborah, Haupt, Axel
Published in The Lancet (British edition) (17.11.2018)
Published in The Lancet (British edition) (17.11.2018)
Get full text
Journal Article
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
Frias, Juan Pablo, Nauck, Michael A., Van, Joanna, Benson, Charles, Bray, Ross, Cui, Xuewei, Milicevic, Zvonko, Urva, Shweta, Haupt, Axel, Robins, Deborah A.
Published in Diabetes, obesity & metabolism (01.06.2020)
Published in Diabetes, obesity & metabolism (01.06.2020)
Get full text
Journal Article
Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program
Frías, Juan Pablo, Galindo, Rodolfo J, Wang, Hui, Malik, Raleigh E, Chivukula, K Karthik, Maldonado, Juan M
Published in The journal of clinical endocrinology and metabolism (18.01.2024)
Published in The journal of clinical endocrinology and metabolism (18.01.2024)
Get full text
Journal Article
Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes
Pablo Frias, Juan, Lorenz, Martin, Roberts, Michelle, Dex, Terry, Schmider, Wolfgang, Hurst, William, Skolnik, Neil
Published in Current medical research and opinion (03.04.2019)
Published in Current medical research and opinion (03.04.2019)
Get more information
Journal Article
Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials
Aroda, Vanita R., Frias, Juan Pablo, Ji, Linong, Niemoeller, Elisabeth, Nguyên‐Pascal, My‐Liên, Denkel, Karl, Espinasse, Melanie, Guo, Hailing, Baek, SeungJae, Choi, JaeDuk, Lingvay, Ildiko
Published in Diabetes, obesity & metabolism (01.08.2023)
Published in Diabetes, obesity & metabolism (01.08.2023)
Get full text
Journal Article
The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device
Frias, Juan Pablo, Koren, Michael J., Loizeau, Virginie, Merino-Trigo, Ana, Louie, Michael J., Raudenbush, Mary Alice, Batsu, Isabela
Published in Clinical therapeutics (01.01.2020)
Published in Clinical therapeutics (01.01.2020)
Get full text
Journal Article
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
Handelsman, Yehuda, Chovanes, Christina, Dex, Terry, Giorgino, Francesco, Skolnik, Neil, Souhami, Elisabeth, Stager, William, Niemoeller, Elisabeth, Frias, Juan Pablo
Published in Journal of diabetes and its complications (01.03.2019)
Published in Journal of diabetes and its complications (01.03.2019)
Get full text
Journal Article
Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial
Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio
Published in Diabetes, obesity & metabolism (01.09.2020)
Published in Diabetes, obesity & metabolism (01.09.2020)
Get full text
Journal Article
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Frias, Juan Pablo, Bastyr, Edward J., Vignati, Louis, Tschöp, Matthias H., Schmitt, Christophe, Owen, Klara, Christensen, Rune Haubo, DiMarchi, Richard D.
Published in Cell metabolism (01.08.2017)
Published in Cell metabolism (01.08.2017)
Get full text
Journal Article
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
Frias, Juan Pablo, Choi, JaeDuk, Rosenstock, Julio, Popescu, Luiza, Niemoeller, Elisabeth, Muehlen-Bartmer, Isabel, Baek, Seungjae
Published in Diabetes care (01.07.2022)
Published in Diabetes care (01.07.2022)
Get full text
Journal Article
Obesity among Latinx people in the United States: A review
Alemán, José Orlando, Almandoz, Jaime P., Frias, Juan Pablo, Galindo, Rodolfo J.
Published in Obesity (Silver Spring, Md.) (01.02.2023)
Published in Obesity (Silver Spring, Md.) (01.02.2023)
Get full text
Journal Article
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Mathieu, Chantal, Dandona, Paresh, Gillard, Pieter, Senior, Peter, Hasslacher, Christoph, Araki, Eiichi, Lind, Marcus, Bain, Stephen C, Jabbour, Serge, Arya, Niki, Hansen, Lars, Thorén, Fredrik, Langkilde, Anna Maria
Published in Diabetes care (01.09.2018)
Published in Diabetes care (01.09.2018)
Get full text
Journal Article
78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)
LUDVIK, BERNHARD, GIORGINO, FRANCESCO, JODAR, ESTEBAN, FRIAS, JUAN PABLO, LANDO, LAURA FERNANDEZ, BROWN, KATELYN, BRAY, ROSS, RODRÍGUEZ, ÁNGEL
Published in Diabetes (New York, N.Y.) (01.06.2021)
Published in Diabetes (New York, N.Y.) (01.06.2021)
Get full text
Journal Article